Pacific Biosciences

Pacific Biosciences (PacBio) is the original pioneer of long-read DNA sequencing — the SMRT (Single Molecule Real-Time) technology that reads DNA fragments tens of thousands of bases long versus Illumina's short reads of 150 to 300 bases. Long reads matter for genomics applications where structural variants, repetitive regions, and full-length transcripts are critical: clinical hereditary disease diagnosis, plant genomics, microbiome research, and personalized cancer-genome assembly.

The market hates this stock for three reasons. First, Oxford Nanopore (UK competitor) eats the lower end of the long-read market. Second, Illumina is rolling out its own long-read product (Complete Long Read) which threatens PacBio's high-end labs. Third, PacBio cash burn pushed the company to a 2024 dilutive capital raise that sent shares from $9 to under $2. Trailing EPS minus 0.41, EV/EBITDA negative — clinical-stage-economics, not yet a profitable sequencer.

BlackRock and Vanguard are passive holders. Casdin Capital (life-sciences hedge fund) had a position but reduced through 2024. No major activist or strategic. Insider buying has been limited.

Traditional valuation does not apply. EV/Sales 4.86 on $160M revenue, negative book equity (low denominator drives the P/B 140 number), high cash burn. The stock is an option on either a Revio-driven installed-base flywheel or an M&A premium. Probability of zero is real (20 to 30 percent) but probability of $5 to $8 takeout is also real.

1. :
2. :
3. :

PACB is a binary biotech-economics name dressed as a medical-device company. I would only own this in a long-read-sequencing basket alongside Oxford Nanopore (LSE: ONT) and as a 0.3 to 0.5 percent option-style position. The upside if Revio compounds and M&A happens is 3x to 5x; the downside is 80 percent drawdown to dilutive raise. Not investing — speculating with a thematic hedge.